Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PMEA 2014

- PMLiVE

Novo enrols first patient in Tresiba cardiovascular trial

Milestone comes as diabetes-focused company reports solid growth

- PMLiVE

Novo Nordisk recalls insulin

Batches of prefilled NovoMix 30 pens found to have incorrect amount of diabetes treatment

- PMLiVE

Novo Nordisk wins US approval for haemophilia treatment

NovoEight will be launched alongside MixPro device after gaining FDA licence

- PMLiVE

Novo’s Wagtmann joins Innate as chief scientific officer

He was previously head of inflammation biology at Danish pharma company

- PMLiVE

Novo backs Victoza’s prospects in Alzheimer’s

Chief science officer says phase III trial could begin in three years

- PMLiVE

EASD 2013: Novo Nordisk’s diabetes combination IDegLira impresses in study

Mix of Tresiba and Victoza helps 81 per cent achieve blood sugar target in phase III

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

- PMLiVE

Malcolm Badger joins emotive

Takes up role as creative director after five years with Havas Life

- PMLiVE

Novo Nordisk’s Victoza shows Alzheimer’s benefits

UK scientists say the diabetes drug could reverse effects of dementia

Harnessing social media for campaign success

Digital excellence from Ruder Finn's meningitis work for Novartis

- PMLiVE

New head for Novo Nordisk in North America

US diabetes care specialist Novo Nordisk Inc has a new president

- PMLiVE

Novo says three year wait for Tresiba safety data

Trial will start this year comparing insulin’s cardiovascular safety to that of Lantus

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links